化合物PF6260933
|
|
|
- CAS号:
- 1811510-56-1
- 英文名:
- PF-6260933
- 英文别名:
- PF-6260933;PF06260933;[3,3'-Bipyridine]-6,6'-diamine, 5-(4-chlorophenyl)-;PF 06260933;PF06260933;PF6260933;PF 6260933;PF-6260933;inhibit,MAP4K,MAPK Kinase Kinase Kinase,PF 06260933,PF06260933,Inhibitor,PF-06260933
- 中文名:
- 化合物PF6260933
- 中文别名:
- 化合物PF6260933;5-(4-氯苯基)-[3,3'-联吡啶]-6,6'-二胺
- CBNumber:
- CB53344890
- 分子式:
- C16H13ClN4
- 分子量:
- 296.75
- MOL File:
- 1811510-56-1.mol
|
|
|
化合物PF6260933化学性质
-
沸点:
-
483.8±40.0 °C(Predicted)
-
|
-
密度:
-
1.330±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMF: 1 mg/ml; DMSO: 1 mg/ml; Ethanol: insol; PBS (pH 7.2): insol
-
|
-
形态:
-
A solid
-
|
-
酸度系数(pKa):
-
5.04±0.13(Predicted)
-
|
化合物PF6260933性质、用途与生产工艺
PF-6260933 (PF-06260933)是MAP4K4抑制剂，IC50为3.7 nM，具有良好的激酶组选择性。
| Target | Value |
MAP4K4
()
|
3.7 nM
|
PF-06260933 treatment of human aortic endothelial cell (EC) robustly prevents TNF-α-mediated endothelial permeability
in vitro
, similar to MAP4K4 knockdown.
In the mice model, PF-06260933 treatment does not alter plasma lipid content, although reductions in glucose levels are observed, which is consistent with whole-body-inducible Map4k4 knockout animals. PF-06260933 administration ameliorates further plaque development and/or promotes plaque regression in this animal model (46.0% versus 25.5%), and a reduction in plasma glucose as well as lipid content is also observed.
化合物PF6260933
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/01/25 | HY-19562 | PF-06260933 | | 1 mg | 545元 |
| 2024/01/25 | HY-19562 | 化合物PF6260933
PF-06260933 | 1811510-56-1 | 5 mg | 1200元 |
1811510-56-1, 化合物PF6260933 相关搜索:
- 药靶配体
- 5-(4-氯苯基)-[3,3'-联吡啶]-6,6'-二胺
- 化合物PF6260933
- 1811510-56-1
- inhibit,MAP4K,MAPK Kinase Kinase Kinase,PF 06260933,PF06260933,Inhibitor,PF-06260933
- PF 06260933;PF06260933;PF6260933;PF 6260933;PF-6260933
- PF06260933
- [3,3'-Bipyridine]-6,6'-diamine, 5-(4-chlorophenyl)-
- PF-6260933